Recent drug recalls (e.g., valsartan and ranitidine) linked to
the discovery of nitrosamine impurities have led to increased regulatory
scrutiny in the manufacturing process of marketed medicines, notably
for determining any sources of risk for nitrosamine (or related N-nitroso compound) formation within the manufacturing process.
This review seeks to aid the risk assessment process through identifying
known conditions and reactants through which N-nitroso
compounds can be formed.